Abstract
Medarex is developing the antibody MDX-060 for the potential treatment of CD30+ lymphomas, such as Hodgkin's disease and anaplastic large cell lymphomas. Phase I/II clinical trials were underway by December 2002.
MeSH terms
-
Animals
-
Antibodies, Monoclonal*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Clinical Trials as Topic
-
Drug Screening Assays, Antitumor
-
Hodgkin Disease / drug therapy*
-
Hodgkin Disease / immunology
-
Humans
-
Ki-1 Antigen / immunology*
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Lymphoma, Large B-Cell, Diffuse / immunology
Substances
-
Antibodies, Monoclonal
-
Antineoplastic Agents
-
Ki-1 Antigen
-
iratumumab